Warren Buffett's Berkshire Hathaway, Elon Musk's Tesla And Eli Lilly Could Be Next Trillion-Dollar Companies After Nvidia's Rapid Ascension: Jim Cramer
Portfolio Pulse from Benzinga Neuro
Jim Cramer has named Eli Lilly (LLY), Berkshire Hathaway (BRK), and Tesla (TSLA) as potential candidates to reach a trillion-dollar market cap, following Nvidia's (NVDA) recent achievement. Eli Lilly is noted for its promising GLP-1 drugs, Berkshire Hathaway for the rising cost of auto insurance, and Tesla for its new models. Broadcom (AVGO) was also mentioned but is seen as less likely to reach the milestone soon.
February 27, 2024 | 4:05 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Broadcom's potential to reach a trillion-dollar market cap is questioned by Cramer, despite its innovative CEO and partnership with Nvidia.
Cramer's skepticism about Broadcom reaching a trillion-dollar valuation soon is based on its current market position and challenges.
CONFIDENCE 60
IMPORTANCE 40
RELEVANCE 60
NEUTRAL IMPACT
Nvidia has recently achieved a trillion-dollar market cap, setting a high benchmark for other companies.
Nvidia's achievement of a trillion-dollar market cap is a significant milestone, influencing perceptions of what is possible for other tech companies.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Tesla's potential to reach a trillion-dollar market cap is seen as less likely by Cramer, despite the potential boost from new models.
While new models could increase Tesla's value, Cramer views it as less likely to reach the trillion-dollar mark compared to others.
CONFIDENCE 65
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Berkshire Hathaway's valuation could benefit from the rising cost of auto insurance, positioning it as a potential trillion-dollar company.
As auto insurance costs rise, Berkshire Hathaway's diverse portfolio, including its insurance operations, could see significant value appreciation.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Eli Lilly's potential to reach a trillion-dollar market cap is highlighted by its promising GLP-1 drugs for diabetes, obesity, and possibly cardiovascular and liver diseases.
The optimism around Eli Lilly's GLP-1 drugs for treating a range of diseases could significantly boost investor confidence and its market valuation.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90